Amyotrophic neuralgia of atypical presentation associated with exposure to a hepatitis B vaccine

Publication date: Available online 20 February 2020Source: Neurología (English Edition)Author(s): J.A. Crespo Burillo, Á. Gimenez Muñoz, J.M. Pérez Trullén
Source: Neurologia - Category: Neurology Source Type: research

Related Links:

In the past, Hepatitis B donors have been declined in patients who have not been vaccinated by the Hepatitis B vaccine. There is concern that these donors would transmit Hepatitis B to the recipient if they are not vaccinated. There is treatment available for these Hepatitis B infections, however, it has not been established as to its efficacy in patients on immunosuppression. In addition, hepatitis viruses have been reported to affect the endothelium of vital organs. Hepatitis B may injure the endothelium of the coronary vascular tree and could potentially result in a greater development of cardiac allograft vasculopathy ...
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (1224) Source Type: research
It turns out that many more people than just boomers can benefit from testing for hepatitis C, a viral infection of the liver that often causes no symptoms. If you’re a member of the baby-boom generation (born between 1946 and 1964), your doctor may have already recommended the test. But those born before or after those years may not have known about the test unless they had a risk factor for hepatitis C, such as a history of intravenous drug use. A new guideline is changing this approach. Why the different recommendations for baby boomers? In 2012–2013, the CDC and the US Preventive Services Task Force (USPSTF...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Digestive Disorders Health Infectious diseases Men's Health Sexual Conditions Women's Health Source Type: blogs
ConclusionIn this analysis, we observed that 14% of SIV adults had LTBI, 27% of SIVH had at least one intestinal parasite, and about half of SIV children had EBLL. Most adults were susceptible to HBV. In general, prevalence of infection was higher for most conditions among Afghan SIVH compared to Iraqi SIVH. The Centers for Disease Control and Prevention (CDC)Guidelines for the US Domestic Medical Examination for Newly Arriving Refugees can assist state public health departments and clinicians in the care of SIVH during the domestic medical examination. Future analyses can explore other aspects of health among resettled SI...
Source: PLoS Medicine - Category: Internal Medicine Authors: Source Type: research
Condition:   Hepatitis B Intervention:   Biological: Hepatitis B recombinant vaccine Sponsor:   Pontificia Universidad Catolica de Chile Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article highlights key developments in antiviral/immunomodulatory therapy, the rationale for these approaches, and possible therapeutic regimens.
Source: Gastroenterology Clinics of North America - Category: Gastroenterology Authors: Source Type: research
Basel, 27 March  2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) as well as two supplemental New Drug Applications (sNDA) for Xofluza® (baloxavir marboxil). The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient option for children and those who have difficulty swallowing. In addition, the application seeks approval of Xofluza for the treatment of acute uncomplicated influenza in otherwise healthy children aged one to l ess th...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Right now, many people are hoping for a vaccine to protect against the new coronavirus. While that’s still on the horizon, new research suggests that families who do vaccinate their children may not be following the recommended schedule. Vaccines are given on a schedule for a reason: to protect children from vaccine-preventable disease. Experts designed the schedule so that children get protection when they need it — and the doses are timed so the vaccine itself can have the best effect. When parents don’t follow the schedule, their children may not be protected. And yet, many parents do not follow the sc...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Adolescent health Children's Health Parenting Vaccines Source Type: blogs
Condition:   Hepatocellular Carcinoma Interventions:   Drug: Cyclophosphamide;   Biological: Multiple Signals loaded Dendritic Cells Vaccine Sponsors:   Yuehua Huang;   Sun Yat-sen University;   Nanfang Hospital of Southern Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
amvis Hepatitis B virus (HBV) infects the liver resulting in end stage liver disease, cirrhosis, and hepatocellular carcinoma. Despite an effective vaccine, HBV poses a serious health problem globally, accounting for 257 million chronic carriers. Unique features of HBV, including its narrow virus–host range and its hepatocyte tropism, have led to major challenges in the development of suitable in vivo and in vitro model systems to recapitulate the HBV replication cycle and to test various antiviral strategies. Moreover, HBV is classified into at least nine genotypes and 35 sub-genotypes with distinct geograph...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
Cork, Ireland, March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that Health Canada has approved CABENUVA™ (cabotegravir and rilpivirine extended release injectable suspensions), the first and only once-monthly, long-acting regimen for the treatment of HIV-1 infection in adults. CABENUVA™ is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]). CABENUVA™, a co-packaged kit with t...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Brain | Hepatitis | Hepatitis B | Hepatitis Vaccine | Neurology | Vaccines